The market reacted quickly after the release of the positive results of the three rounds of the MRNA cancer vaccine developed jointly by Moderna and Meshadon. According to news, Moderna ' s stock price rose by about 131 per cent on Wednesday, and investors who were left empty of the unit suffered from large book losses.
Three tests have reached two main endpoints.
According to the two companies, the Intelpath-001 three-phase test evaluation was carried out by Intismeran autogene in conjunction with Keytruda, for melanoma patients in the IIB to IV periods that had been surgically removed.
The experiment reached the two main end points of the life cycle and the no-distant transfer period, meaning that the combination therapy performed better in post-operative assistive treatment than the standard options available for the separate use of Keytruda.
This is the first positive three-stage result of an individualized new antigen therapy and the first positive data on cancer treatment in a three-stage test.
Vaccines tailored to the patient ' s tumor characteristics
The therapy, also known as V940 or mRNA-4157, is not a product produced in a single mass. The patient's tumours are sequenced, the specific mutations are identified and the individual MRNA vaccine is designed accordingly.
The effect is to enable the human body to generate new antiprotein fragments associated with these mutations, thus helping the immune system to identify and attack residual cancer cells. Keytruda, which is associated with PD-1 immunotherapy, enhances immunocellular activity.
They are used jointly with the aim of further removing possible cancer cells after the operation and reducing the risk of relapse and transfer.
The price of the stock soars up and leads to a headback.
This test results are particularly significant for Moderna. Prior to the cooling down of the New Crown Vaccine business, the company had been under pressure to grow and had been one of the large capitalizations of the United States stock with a high level of empty space.
With good news coming out, there was a quick recovery in the market. According to the article, traders who did empty Moderna faced a market value deficit of approximately $4.8 billion, while the Unit occupied approximately 13.5 per cent of the free circulation unit.
Against the background of high-altitude silos, the sharp rise in stock prices tends to force some of the borrowers to return to stock silos, further magnifying the increase.
We'll continue to observe the total life period.
Current disclosures are concentrated on two key endpoints. The experiment will continue and will be followed by an assessment of the total lifetime and other secondary endpoints.
This means that while the first three results have led to a re-evaluation of Moderna ' s tumour line value in the market, the long-term clinical performance of the treatment needs further data disclosure.